N-myristoyltransferase inhibition is synthetic lethal in MYC-deregulated cancers
Authors
- G.A. Lueg
- M. Faronato
- A. Gorelik
- A.G. Grocin
- E. Caamano-Gutierrez
- F. Falciani
- R. Solari
- R. Carr
- A.S. Bell
- E. Bartlett
- J.A. Hutton
- M. Llorian-Sopena
- P. Chakravarty
- B. Brzezicha
- M. Janz
- M.J. Garnett
- D.P. Calado
- E.W. Tate
Journal
- bioRxiv
Citation
- bioRxiv
Abstract
Human N-myristoyltransferases (NMTs) catalyze N-terminal protein myristoylation, a modification regulating membrane trafficking and interactions of >100 proteins. NMT is a promising target in cancer, but a mechanistic rationale for targeted therapy remains poorly defined. Here, large-scale cancer cell line screens against a panel of NMT inhibitors (NMTi) were combined with systems-level analyses to reveal that NMTi is synthetic lethal with deregulated MYC. Synthetic lethality is mediated by post-transcriptional failure in mitochondrial respiratory complex I protein synthesis concurrent with loss of myristoylation and degradation of complex I assembly factor NDUFAF4, followed by mitochondrial dysfunction specifically in MYC-deregulated cancer cells. NMTi eliminated MYC-deregulated tumors in vivo without overt toxicity, providing a new paradigm in which targeting a constitutive co-translational protein modification is synthetically lethal in MYC-deregulated cancers. ONE-SENTENCE SUMMARY: N-myristoyltransferase inhibition leads to post-transcriptional complex I failure and cell death in MYC-deregulated cancers.